Loading...
•
Dec 31, 2021
Atara Q4 2021 Earnings Report
Reported financial results for the fourth quarter and full year 2021, along with business highlights and key upcoming catalysts for 2022.
Key Takeaways
Atara Biotherapeutics reported a net loss of $93.3 million for Q4 2021, with cash, cash equivalents, and short-term investments totaling $371.1 million as of December 31, 2021. The company is progressing its pipeline, including tab-cel and ATA188, but faces regulatory challenges with the FDA regarding tab-cel's BLA submission in the U.S.
Atara's EMA filing for tab-cel is progressing as planned, with anticipated EU approval in Q4 2022 under Accelerated Assessment.
ATA188 was granted FDA Fast Track designation in both non-active PPMS and non-active SPMS, with Phase 2 EMBOLD study interim analysis planned for Q2 2022.
Atara entered a long-term strategic manufacturing partnership with Fujifilm, receiving an upfront cash payment of USD 100 million.
Further engagement and alignment are required with the FDA to determine the path forward for a BLA submission in the U.S. for tab-cel.
Forward Guidance
Atara believes that its cash as of December 31, 2021, together with the anticipated $100.0 million payable to Atara upon closing of the strategic transaction with FDB, will be sufficient to fund the Company’s planned operations into the fourth quarter of 2023
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...